Abstract: This method for measuring pulmonary surfactant protein D includes a step of bringing a sample containing pulmonary surfactant protein D into contact with an insoluble carrier on which an anti-pulmonary surfactant protein D monoclonal antibody has been immobilized, and a step of detecting a complex of the pulmonary surfactant protein D and at least two of the anti-pulmonary surfactant protein D monoclonal antibodies, wherein the insoluble carrier supports only one type of antibody as the anti-pulmonary surfactant protein D monoclonal antibody.

Abstract: A problem to be solved is to further improve the specificity for free AIM of an antibody specifically reacting with free AIM and to diagnose NASH without imposing a burden on patients and medical staffs. The problem can be solved by an immunoassay method for free AIM in a biological sample containing complex AIM and free AIM, and the method comprises bringing the biological sample into contact with an antibody specifically reacting with free AIM in a presence of an anti-IgM antibody.

Abstract: A problem to be solved is to improve the specificity of an anti-AIM antibody for free AIM in a biological sample containing complex AIM and free AIM. The problem can be solved by an immunoassay method for measuring an amount of free AIM in a biological sample containing complex AIM and free AIM, and the method comprises bringing the biological sample into contact with an anti-AIM antibody in the presence of an anti-IgM antibody.

Abstract: The present invention provides an immunoassay method for assaying SARS-CoV-2 in a biological sample, including using two types of monoclonal antibodies or antibody fragments thereof that bind to a peptide fragment having 30 or less consecutive amino acids in a nucleocapsid protein of SARS-CoV-2, wherein the two types of monoclonal antibodies or antibody fragments thereof recognize different epitopes

Abstract: The present invention provides an immunoassay method for assaying SARS-CoV-2, including a step of contacting a biological sample with a monoclonal antibody or an antibody fragment thereof that binds to a nucleocapsid protein of SARS-COV-2, wherein the monoclonal antibody or the antibody fragment thereof binds to the SARS-CoV-2 treated with a serine protease.

Abstract: A problem to be solved is to detect only free AIM in a biological sample containing complex AIM and free AIM. The problem can be solved by an immunoassay method for free AIM in a biological sample using an anti-AIM monoclonal antibody having a property of reacting with free AIM and not reacting with complex AIM, wherein the anti-AIM monoclonal antibody is an antibody binding to an epitope in the SRCR2 domain of human AIM.

Abstract: A problem to be solved is to further improve the specificity for free AIM of an antibody specifically reacting with free AIM and to diagnose NASH without imposing a burden on patients and medical staffs. The problem can be solved by an immunoassay method for free AIM in a biological sample containing complex AIM and free AIM, and the method comprises bringing the biological sample into contact with an antibody specifically reacting with free AIM in a presence of an anti-IgM antibody.

Abstract: A problem to be solved is to improve the specificity of an anti-AIM antibody for free AIM in a biological sample containing complex AIM and free AIM. The problem can be solved by an immunoassay method for measuring an amount of free AIM in a biological sample containing complex AIM and free AIM, and the method comprises bringing the biological sample into contact with an anti-AIM antibody in the presence of an anti-IgM antibody.

Abstract: A method and a diagnostic agent kit for detecting viral liver cancer having excellent sensitivity and specificity are provided. The problem can be solved by a method for detecting viral liver cancer, comprising measuring an amount of free AIM in a biological sample from a subject and comparing the measured amount of free AIM with a reference value.